Floatz Rating
B58/100
Confidence
Indicative
Sponsor
InterMune
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00075998CT.gov The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) | — | Terminated | — | — | — |
NCT00076635CT.gov An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF | — | Terminated | — | — | — |
NCT00052052CT.gov An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) | — | Completed | — | — | — |
NCT00052039CT.gov A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Interferon Gamma-1B (this asset) | InterMune | P3 | B · 58 |
| Carboplatin | Jiangmen Central Hospital | P3 | BB |
| Theophylline | NCIC Clinical Trials Group | P3 | BB |
| Lumacaftor | Vertex Pharmaceuticals Incorporated | P3 | BB |
| Ivacaftor | University of British Columbia | P3 | BB |
| Pembrolizumab | Sarah Goldberg | P3 | B |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Jiangmen Central Hospital | P3 | B |
| Rivoceranib | Sichuan Cancer Hospital and Research Institute | P2 | B |
+41 more in the Lung Disorder cohort
Other indications for Interferon Gamma-1B
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pulmonary Fibrosis | — | P3 | BB · 64 |
| Cancer Of Unknown Primary Site | — | P2 | BB · 64 |
| Osteopetrosis | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Interferon Gamma-1B in Lung Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/interferon-gamma-1b-lung-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →